Senior Bioanalytical & Proteomics Scientist | Biopharma & Biotech R&D
Life sciences scientist with 10+ years of high-impact experience across premier research institutes and global industry leaders, including A*STAR (IMCB Singapore) and Thermo Fisher Scientific. Specialized in high-resolution mass spectrometry (HRMS), quantitative proteomics (DDA, DIA-SWATH), biotherapeutic antibody validation (900+ validated), and regulated lab operations.
Comprehensive mastery of high-resolution LC-MS/HRMS systems (SCIEX 7600 Zeno-TOF, Waters Xevo TQ-S). Architect of qualitative and quantitative proteomic workflows (DDA, DIA-SWATH, DIA-NN) across complex biological matrices including plasma, tissues, cell lines, and cultivated alternative proteins.
Led the end-to-end development of 100+ and validation of 900+ commercial antibodies for Thermo Fisher's flagship Invitrogen brand. Deep domain expertise in multi-parametric assays: Western blotting, ICC, IHC, flow cytometry, ChIP, and High-Content Screening (HCS).
Experienced scientific platform manager coordinating cross-functional projects across academic institutes (BII, SIgN) and biopharma industry partners (Meatiply). Proven track record in laboratory operations, SOP standardization, root-cause analytical troubleshooting, PPI/Kaizen operational excellence, and team mentorship.
Proven impact across international biomedical research hubs, leading mass spectrometry platforms, antibody research, and proteomics.
Spearheaded cell-based and biochemical assay development for characterization and validation of antibody candidates in a regulated environment. Contributed to SOP authoring, quality assurance audits, and cross-functional project milestone execution.
Developed 100+ and validated 900+ commercial antibodies under the Invitrogen portfolio across Western Blotting, ICC, Flow Cytometry, ChIP, and IHC. Mastered high-throughput imaging on iBright™ FL1500 and CellInsight CX7 LZR Pro HCS platforms.
Supported OEM validation pipelines and successfully launched 300+ fluorescent-tagged antibodies for high-content cell imaging. Delivered 20+ technical presentations to promote customer adoption and scientific engagement.
Evaluated the oncogenic transcription factor Pax3 as a therapeutic target in pediatric solid tumors and investigated Pax3 molecular interactions across neuronal cell lines (Neuro2A, IMR-32, SHSY-5Y).
Investigated tumor progression in clinical breast cancer tissue samples via histopathology, immunohistochemistry (IHC), fluorescence microscopy, and photoacoustic spectroscopy. Resulted in high-impact publication in ACS Sensors.
School of Molecular Biosciences: Engineered a Streptococcus-based protein subunit vaccine utilizing solid-phase peptide synthesis (SPPS), RP-HPLC purification, and mass spectrometry characterization.
Peer-reviewed research across noninvasive diagnostics, translational peptide therapeutics, and antimicrobial countermeasures in high-impact journals.
Hands-on mastery of cutting-edge analytical hardware, computational proteomics pipelines, and molecular assays.
Recognized for technical excellence, critical crisis project leadership, and continuous professional growth.
Conferred for the successful development and patent filing of novel cell-penetrating peptides tailored for fluorescence imaging applications.
Awarded for exceptional commitment to serving mission-critical projects during the COVID-19 pandemic and driving successful on-time delivery.
Formal training in scope definition, work breakdown structures, risk mitigation, and scientific milestone delivery.
Focus on product lifecycle management, user needs analysis, and cross-functional go-to-market strategies for biotech tools.
GPA: 3.9 / 5.00 • First Class with Distinction
GPA: 4.1 / 5.00 • First Class with Distinction
“Nitufa is an exceptional scientist whose bioanalytical rigor and deep technical command in mass spectrometry and antibody characterization consistently elevated our team’s deliverables. Her ability to systematically troubleshoot complex assays, author robust SOPs, and collaborate cross-functionally makes her a tremendous asset to any high-performing biopharma R&D organization.”
Interested in discussing a proteomics or bioanalytical role, consulting, or industry collaboration? Reach out directly.
Nitufa welcomes discussions regarding bioanalytical roles, proteomics platform leadership, and scientific collaborations.
Fill in the details below to open your preferred email client with a pre-composed message to Nitufa.